Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma

The aim of our study was to verify the efficacy and tolerability of subcutaneous low doses of interleukin-2 with cisplatin and dacarbazine for malignant melanoma. 24 patients were included. The following schedule was used: cisplatin (CDDP) 100 mg/m2 day 1; darcarbazine (DTIC) 375 mg/m2 days 1–5; rec...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 1996-04, Vol.32 (4), p.730-733
Main Authors: Guida, M., Latorre, A., Mastria, A., De Lena, M.
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
CDDP + DTIC + subcutaneous IL-2
Chemotherapy
Cisplatin - administration & dosage
Cisplatin - adverse effects
Dacarbazine - administration & dosage
Dacarbazine - adverse effects
Female
Humans
Injections, Subcutaneous
Interleukin-2 - administration & dosage
Interleukin-2 - adverse effects
Male
Medical sciences
Melanoma - drug therapy
Melanoma - secondary
metastatic melanoma
Middle Aged
Pharmacology. Drug treatments
Recombinant Proteins - administration & dosage
Remission Induction
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of our study was to verify the efficacy and tolerability of subcutaneous low doses of interleukin-2 with cisplatin and dacarbazine for malignant melanoma. 24 patients were included. The following schedule was used: cisplatin (CDDP) 100 mg/m2 day 1; darcarbazine (DTIC) 375 mg/m2 days 1–5; recombinant interleukin-2 (rIL-2) 4.5 million IU × 2/day days 13–17 and 20–24. The therapy was recycled every 28 days. 10 patients obtained clinical remission (42%), with 2 complete responses (8%) persisting for 12 and 15+ months, and 8 partial responses (35.5%) with a median duration of 5 months. Median survival of all 24 patients was 8 months, 13 months for responders and 6 months for non-responders. Responses were seen predominantly in lymph nodes (48%) and skin-soft tissue (38%), but were also seen in the liver (29%) and lung (14%). Treatment was relatively well tolerated and toxicity was mainly related to chemotherapy.
ISSN:0959-8049
1879-0852
DOI:10.1016/0959-8049(95)00662-1